INVESTIGATION OF CIRCULATING TUMOR DNA (CTDNA) IN PATIENTS WITH NON-METASTATIC TRIPLE-NEGATIVE BREAST CANCER (TNBC) SUBMITTED TO NEOADJUVANT CHEMOTHERAPY

Resumo

Objective: Loss-of-function germline mutation in BRCA1 increases breast cancer risk, especially in the triple-negative
breast cancer (TNBC) subtype. BRCA1 impairment may confer benefit from the treatment with DNA damage-inducing
drugs and PARP1 inhibitors. Patients who respond to neoadjuvant chemotherapy tend to have good outcomes. The aim of
this study was to characterize the resistance to chemotherapy in patients with germline-characterized TNBC by investigating somatic mutations in ctDNA. Methods: Germline genetic testing was done using cancer-predisposing gene panels
(26–126 genes) to classify TNBC as hereditary or sporadic. Somatic mutation identification in tumor (409 cancer-related
gene panel) and screening of ctDNA in plasma samples during treatment were performed. Results: We enrolled 96 TNBC
patients of which 88 were tested for germline variants: 23% (20/88) of cases were hereditary – BRCA1 (16%), BRCA2 (4%),
PALB2 (1%), RAD51D (1%), and TP53 (1%). Tumor mutation burden (TMB) analysis (43 cases) showed that 11.6% had high
and 89.4% had low TMB, not associated with hereditary status. We found, on average, 3 somatic variants per tumor (range
1–7) and used them as tumor marks for screening ctDNA in plasma. Somatic mutations in TP53 were identified in most
tumors (71%). In ctDNA before treatment, detection of at least one tumor mutation was observed in 24 out of 30 patients
(80%), and no association was observed between hereditary status and TMB score. Although ctDNA was not associated
with the residual cancer burden score, ctDNA-positive patients were associated with clinical progression, either at baseline or during monitoring (post-neoadjuvant chemo), and ctDNA identification anticipated progression detected by imaging. Conclusion: Hereditary tumors, markedly due to germline variants in BRCA1, are frequent in TNBC. Tumor-mark
identification using gene panels and ctDNA screening in plasma samples provide valuable information regarding the clinical progression of patients treated with preoperative chemotherapy